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ABSTRACT 
Lipids are known to be important for proper cellular and metabolic functions.  Lipid disorders 
include Tay Sach’s, Gaucher’s,  Neimann-Pick, diabetes, adrenoleukodystrophy (ALD), and 
macular degeneration.  Macular degeneration has been linked to mutations in a lipid elongase, of 
which 7 exist in humans and 20 in the fruit fly, Drosophila melanogaster.  To understand the 
contributions of elongases to development, I surveyed their function in Drosophila using RNAi.  
I identified sit still (sit), whose phenotype suggests a model for neurodegenerative diseases like 
multiple sclerosis. 
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INTRODUCTION 
With an expanding world population, human genetic disorders have become more 
prevalent in society today. Of these, neurodegenerative diseases form a major constituent. Such 
diseases are characterized by the progressive loss of neural tissue over time and pose a growing 
health care challenge to an aging population. For this reason, research on developing therapies 
and finding the molecular causes behind many of these diseases has increased dramatically. 
Often neurodegenerative disorders are caused by lipid-related defects in the body. One 
such example is Tay-Sach’s disease, a lipid storage disorder associated with mental and physical 
disabilities leading to fatality. The underlying defect is insufficient activity of beta-
hexosaminidase A, the enzyme that breaks down gangliosides in the body as needed, which 
causes the accumulation of fatty acid derivatives called gangliosides in the body leading to 
fatality caused by the accumulation of fatty acid derivatives called gangliosides in the body 
(Okada S & O'Brien JS, 1969). 
1.1 Fatty Acids and Elongases 
In all eukaryotic cellular systems, fatty acids, molecules composed of a long hydrocarbon 
chain and a carboxylic acid group, are known to be vital for proper function (Figure 1). They 
may be saturated or unsaturated, and are available to organisms via their diet, or via cellular 
synthesis in the cytosol (Figure 1). Within the endoplasmic reticulum, cytoplasmic fatty acids 
with 16 carbon units (C16) can be converted into long chain fatty acids (LCFAs: C18-23) or very 
long chain fatty acids (VLCFAs: C24-26), by the addition of two carbon units at a time at the 
carboxyl end (Figure 1). Fatty acids function in a plethora of cellular and metabolic functions. 
For example, the hydrophobicity of fatty acids allows for enough forces to create the lipid bilayer 
membrane of cells. Moreover, the breakdown of fatty acids releases great amounts of energy, 
primarily in the form of acetyl-CoA, which is used as a building block for lipids and proteins, or 
further broken down in the citric acid cycle into amino acids or fatty acids. Finally, fatty acids 
are often components of other compounds like hormones and signaling molecules (Tehlivets O, 
Scheuringer K, & Kohlwein SD, 2007). 
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Figure 1: Saturated vs. unsaturated fatty acids. The former has only single bonds, and is ‘saturated’ with 
hydrogen. Only the latter can have additions to become a longer fatty acid 
 
Fatty acids synthesized in the cytosol or taken up in the diet can be converted into 
VLCFAs, which are often esterified (joined by ester or amide linkages) to build sphingolipids, 
glycerophospholipids, triacylglycerols, and, sterol and wax esters. VLCFAs are also thought to 
be important for cellular and metabolic functions, including intracellular signaling and transport 
(Jakobsson A, Westerberg R, & Jacobsson A, 2006). 
In mammals, fatty acid elongation is a four-step process that cycles until a specified 
length is achieved. The first step of this process is believed to be a regulatory condensation step, 
performed by enzymes termed elongases. These are encoded for by a set of genes called Elovl 
(elongation-of-very-long-chain-fatty-acids) and current evidence suggests that all elongases 
utilize a C16 substrate to carry out enzyme-specific elongation leading to distinct fatty acids. 
(Jakobsson A et al., 2006). At least six members of the enzyme family exist in mice and humans, 
while Drosophila has 20 family members; and at least one, elovl4 in humans, has been linked to 
an inherited disorder - Stargadt-like macular degeneration (Li W et al., 2007). 
As discussed, VLCFAs are commonly needed in building lipids required in signaling 
systems. One such example is the pathway for sphingolmyelin, a fatty acid enriched in the 
myelin sheath surrounding neuronal axons, which regulates cell survival (Ariga T, Jarvis WD, & 
Yu RK, 1998). This provides an important clue as to why several neurodegenerative diseases, 
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including Niemann-Pick, Gaucher’s and Fabry’s diseases, stem from lipid-related disorders in 
the body. 
Six of the mammalian elongases, termed ELOVL1-6, have been identified to date. In 
general, elongases can elongate saturated and monosaturated, or polyunsaturated fatty acid 
chains. Consistent with the model that they produce distinct end-products, spatially and 
temporally, they exhibit specific expression patterns throughout the body (Jakobsson A et al., 
2006). Table 1 below summarizes what is known about them to date: 
  8 
 
GENE PROTEIN FUNCTION 
elovl1 ELOVL1 • Related to the synthesis of C26 saturated fatty acids.  
• Reduction in elovl1 expression increases elongation 
defects. 
elovl2 ELOVL2 • Thought to play a role on the synthesis of 
polyunsaturated fatty acids. 
• Function believed to overlap with that of elovl5. 
elovl3 ELOVL3 • Thought to elongate saturated C16-22 fatty acids during 
initial exposure to cold.  
• Needed in brown adipose tissue to form lipid droplets 
when body temperature suddenly drops.  
• Believed to perform a skin-barrier function to prevent 
desiccation. 
(Westerberg R et al., 2004) 
elovl4 ELOVL4 • Point mutation linked to macular degeneration and 
Stargardt-like dystrophy.  
• May be involved in the synthesis of docosahexanoic acid.  
• Expression was also found in thymus and skin. 
• Knockout mutation causes perinatal lethality 
(Li W et al., 2007 Feb 7) 
elovl5 ELOVL5 • Thought to be involved in elongation of C18-20 
polyunsaturated fatty acids. 
elovl6 ELOVL6 • Elongates C12-16saturated fatty acids to C18 but not 
beyond that.  
• Found to be expressed ubiquitously, especially in high 
lipid-containing cells.  
• Deficiency causes insulin resistance and diabetes. 
(Matsuzaka T et al., 2007) 
Table 1: List of human elongases and their known functions (review: Jakobsson et al., 2006) 
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1.2 Model Organisms- Drosophila: 
 Drosophila melanogaster provides as a good model organism to study human diseases 
and develop potential therapeutics. Greater than sixty percent of the human genes are conserved 
in this organism (Rubin GM, 2000). Many of the extracellular and intracellular signaling 
pathways in Drosophila are similar to those of humans (e.g. MAP kinase pathway) (Bier E, 
2005). Moreover, they are small, have short life cycles and are easy to store; and both genetic 
and compound screens can also be performed easily on them. 
 In addition, a wealth of genetic tools exists to manipulate gene function, including the 
UAS-GAL4 system, which has been used extensively for the purposes of this project. Both the 
responder (UAS) strain and the driver (GAL4)  strain- when crossed can trigger misexpression of 
a specified target gene and lead to phenotypes that can then be studied (for review see Duffy JB, 
2002).  
So far, relatively little is known about elongases in Drosophila, even in relation to human 
elongases. Limited studies have linked only 4 out of 20 fly elongases to their function via both 
loss and gain of function experiments (Table 2). 
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ELONGASE/GENE PUTATIVE 
HUMAN 
ORTHOLOG 
FUNCTION 
baldspot/noa ELOVL6/ 
ELOVL3 
• Expressed in the embryonic nervous system,  in 
imaginal discs, fat bodies, malphighian tubules 
and sex gonads 
• Reduced levels lead to impaired motility and 
severely reduced viability 
• Needed for male germline development 
(Jung A, Hollmann M, & Schäfer MA, 2007) 
eloF unknown • RNAi knockdown triggers reduced copulation 
frequency 
• Crucial for female pheromone synthesis 
(Chertemps T et al., 2007) 
elo68α ELOVL1 • Expressed in male genital system 
• Important for synthesis of vaccenyl acetate 
(male pheromone) 
(Chertemps T, Duportets L, Labeur C, & 
Wicker-Thomas C, 2005) 
bond ELOVL7/ 
ELOVL4 
• Loss of function causes failure of dividing 
spermatocytes to cytokinese 
(Szafer-Glusman E et al., 2008) 
Table 2: List of fly elongases and their known functions  
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 Even with the limited knowledge about this set of genes, it appears that elongases are 
critical for a variety of functions, ranging from skin protection in mammals to fertility and 
pheromone production in insects. The specific objective of this project aims to screen a subset of 
elongases in flies with closest homology to human elongases and test their functions in terms of 
fertility, viability, development and neuronal behavior.  
1.3 The UAS-GAL4 system 
The strategy used for testing of elongase function in this proposal was the UAS-GAL4 
system. GAL4 is a transcription activator found in the yeast Saccharomyces cerevisiae. GAL4 
binds to the UAS (upstream activating sequences) element, which activates transcription of the 
downstream gene. Thus, the UAS element, which has GAL4 binding sites, can control the 
expression of a gene of interest (called the responder) through its presence. When GAL4 is 
absent in responder lines, the gene of interest remains transcriptionally silent. This is represented 
in figure 2a. To activate transcription of the gene of interest, the responder lines can be mated to 
the driver lines, strains expressing GAL4 in a tissue specific manner (such as muscle, neuronal, 
wing, etc.). This is shown in figure 2b. The progeny from this cross will often express the 
responder in a transcriptional pattern similar to the driver, i.e. the responder will be expressed in 
a tissue-specific manner like the driver (for review see Duffy JB, 2002). 
 
Figure 2a: No transcriptional activation, since GAL4 has no binding site in the cross 
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Figure 2b: Transcriptional activation of responder caused by GAL4 binding to UAS 
  
 Thus, GAL4 tissue-specific drivers can be used to express genes in specific areas of the 
body. The system is also temperature specific, exhibiting maximal activity at 29 ºC and minimal 
at 16 º C (Duffy JB, 2002). For the purpose of this project, several different tissue-specific drivers 
were used to ‘knock down’ elongases using RNA-mediated gene interference, also called RNAi.  
 
1.4 RNAi as a genetic tool 
 In some systems, the presence of double-stranded RNA (dsRNA) can trigger what is 
called RNA interference. dsRNA molecules can be processed into small interfering RNA 
(siRNA) by the enzyme Dicer. These siRNAs are in turn bound to a helicase and other proteins 
to form the RISC (RNA-induced silencing) complex. Through sequence complementarity, the 
siRNA guides the association of the RISC complex to target mRNA, which is then degraded by 
the RISC complex in a sequence specific, siRNA-dependent fashion (Pratt AJ & Macrae IJ, 
2009) (Figure 3). 
 To assess the function of elongases in Drosophila, this system was combined with the 
UAS-GAL4 system in this project. By ordering strains expressing gene-specific dsRNAs, target 
elongases were ‘knocked down’ in a tissue specific manner by using specific GAL4 drivers. 
Thus, the role of specific elongases could be assessed throughout development in specific tissues 
of the fly body. 
  13 
 
Figure 3: RNA interference. dsRNA gets broken up into siRNA by Dicer. The RISC-siRNA complex forms 
and degrades the target mRNA, ‘knocking down’ protein expression of that mRNA 
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MATERIALS AND METHODS 
As discussed before, there are 20 elongases in the Drosophila proteome. Research in the 
Duffy lab was already being carried out on the baldspot (bals) gene, also called noa. Loss of 
function experiments in the lab demonstrated that bals is vital for female fertility and embryonic 
viability. In contrast, misexpression of bals led to a rough-eye phenotype, likely due to the 
induction of programmed cell death.  
2.1 Selection of RNAi lines 
Apart from the role of bals, I wanted to address the function and specificity of additional 
elongases. By performing a comparative study of elongases, I identified 5 Drosophila elongases 
sharing the greatest similarity to human elongases. Each human elongase was compared to the 
Drosophila proteome using the Basic Local Alignment Search Tool (BLAST) in the NCBI 
database. The top elongases identified in Drosophila were picked to carry out experiments. 
Strains expressing dsRNA specific to each of these elongases (RNAi lines) were then obtained 
ordered from the Vienna Drosophila Stock Center. The gene sequences for each of these RNAi 
lines are given in the Appendix. 
 
2.2 Genetic Crosses 
Six elongases, including bals as a control, were tested with various GAL4 drivers to test 
cell type specificity. These were CY2GAL4, ActGAL4, TubGAL4, C155GAL4, A9GAL4, 
EnGAL4, GMRGAL4, MS1096, 040GAL4, P{GawB}OK376, P{GawB}T80 and 
P{GawB}C179. Virgins from the GAL4 drivers were crossed to the following RNAi UAS 
responder lines: ELO9807 (CG31523), ELO37328 (CG31522), ELO30179 (CG6921), 
ELO48138 (CG2781), ELO43091 (CG5278), and bals47520 (CG3971). Crosses were 
maintained at 20ºC, 25ºC and 28ºC, to control GAL4 activity as needed. Progeny were collected 
and sorted by phenotype, and examined for phenotypic effects. Wild-type flies, w1118, were also 
maintained and crossed to appropriate drivers as needed for experimental controls.  
 The CG31522 line was crossed to additional GAL4 drivers for further specification. 
These were P{GawB}477, P{GawB}D42, {GawB}109(2)80, P{GAL4-sli.S}, P{GAL4-
Mhc.W}, P{GAL4-Mef2.R}, and P{GawB}how24B. 
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2.3 Behavioral Assays 
Progeny from crosses between the CG31522 RNAi line and neural GAL4 drivers were 
tested to check their movement and ability to orient properly. For this purpose, a set number of 
flies were placed into an empty vial, vortexed for 10 seconds, and observed for a further 15 
seconds to see how many were able to upright themselves and climb up the sides of the vial. The 
progeny were kept at room temperature and tested between 2-4 days of eclosion. Progeny of 
complementation crosses between CG31522 mutations were also tested. 
 
2.4 Time Shift Assays 
To determine the state of development when CG31522 function is required, temperature 
shift experiments were carried out. For this, we had four vials of the cross between the CG31522 
RNAi responder and C155GAL4: two at 20ºC, one at 25ºC and one at 28ºC. Vials were flipped 
everyday and kept at their respective temperatures. Each vial from 20ºC was shifted to the two 
higher temperatures after each successive day of development, i.e. at 24 hours, then 48 hours, 
then 76 hours, and so on. The vials at the higher temperatures were also shifted down to 20ºC in 
the same manner. This was done to increase GAL4 activity and consequently CG31522 
knockdown at higher temperatures, and decrease GAL4 activity and CG31522 knockdown at 
20ºC. Flies collected all vials were assessed in the behavioral assay above to characterize any 
behavioral defects. 
 
2.5 Loss of Function crosses 
Existing  mutation and deficiency lines for CG31522 were searched for at the 
Bloomington Drosophila Stock Center. Two of these were transposable element inserts: 
P{wHy}DG02703 and P{SUPor-P}CG31522KG01294, at different sites in CG31522. The other 
stock (BS#9224) obtained was a chromosomal deletion Df(3R)ED5071encompassing CG31522. 
All of these lines were then used in inter se complementation crosses and assessed for 
homozygous viability.   
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2.6 Generation of DNA constructs 
i) Ordering cDNA 
cDNAs for all the selected genes (except bals) were identified on FlyBase: GH22993 for 
CG31522, RE58951 for CG5278, GH 09808 for CG31523, LD14839 for CG6921 and 
RE49985 for CG2781;and ordered from the Drosophila Genomic Resource Center. Clones 
were transformed, grown on appropriate antibiotic plates, miniprepped and checked via 
restriction enzyme analysis on agarose gels, to ensure the correct clones were received. GH 
22993 and GH 09808 were checked on chloramphenicol plates and all others on ampicillin 
plates. Flies for all cDNA clones were generated in Gene Construction Kit. 
 
ii) Generating the Clone 
To create a responder line for CG31522, Gateway cloning was carried out. For this, the 
CG31522 template GH22993 was used (see Appendix).  To create an entry clone using site-
specific recombination, primers (W100 and W101) to the coding region were designed in 
GCK. PCR was then used to amplify CG31522 with attB1 and attB2 recombination sites on 
the 5’ (W100) and 3’ (W101) ends respectively. With the help of Prachi Gupta, a modified 
PCR product with the CG31522 gene and attB1.1 and B2.1 sites was also created. 
Thus, as shown in figure 4, the first step in Gateway cloning was to generate the PCR 
product. The next step involved using a donor vector, a ‘P donor’ to undergo a BP reaction 
with the gel purified PCR product to form the entry clone. The P donor has attP1 and P2 sites 
that recombine with the attB1 and B2 sites (or B1.1 and B2.1), forming the entry clone, 
which contained the gene of interest (CG31522) flanked by attL1 and L2 sites. Finally, an 
LR reaction was carried out where the entry clone was recombined with the destination 
vector (pUASTa6Xhis/V5 with attR1 and R2 sites). Recombination in this case gave the final 
expression clone - CG31522 under the control of UAS sequences and flanked by attB1 and 
B2 sites. 
  17 
 
Figure 4: Gateway cloning and its steps 
At every step of the entire process, every reaction was followed by transformation on 
plates, then minipreps of picked colonies and restriction digestion analysis.  Qiagen kits were 
used for all mini-preps, maxi-preps, PCR purification and gel extraction as needed. After 
confirming the sequence of the final UAS-CG31522 clone, this DNA was sent to Genetic 
Services, Inc. for injection into Drosophila embryos and generation of transgenic flies.   
 
2.7 Generation of UAS-CG31522 transgenics 
After the DNA had been maxiprepped and sent to Genetic Services, Inc. for injection into 
w1118 Drosophila embryos, injected larvae were sent back so that they could be screened 
transgenics could be performed. Two vials of injected embryos were sent back- A and B. Adults 
from the injected embryos (G0) were single-pair mated to either w1118 females or males (3 or 4 of 
each at one time) and the progeny (F1) were screened for putative transgenics based on the 
presence of eye color. Transgenics from G0 were assumed to be independent insertions. In the F1 
generation, progeny with eye color were picked out and separated into vials. Vial A produced 4 
transgenic males and 4 transgenic females in the F1 generation, while Vial B produced 1 
transgenic male and 2 females in the F1.  
Extra duplicate transgenic flies obtained from the F1 were also separated and crossed to 
C155mCD8::GFP females and males to initially check for any phenotype associated with 
BP reaction 
LR reaction 
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misexpression. Based on these preliminary tests high levels of CG31522 misexpression appears 
to be lethal.  
Transgenic flies from independent insertions at the F2 generation were also crossed to 
second and third chromosome balancers- Sp/CyO and Ly/TM3,Sb, respectively. Heterozygous 
progeny with a copy each of the transgene and the balancer (CyO or TM3,Sb) were picked and 
outcrossed to w1118 flies to map the location of the transgene.  Based on this mapping, 
appropriately balanced stocks will then be generated. 
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RESULTS 
 
3.1 Selection of RNAi lines 
 RNAi responder lines for the five elongases selected were obtained. Table 3 details these 
RNAi lines with respect to the location (chromosome) of the inserts and their viability. 
 
Transformant ID Gene Chromosome Viability 
ELO 9807 CG31523 1 Viable 
ELO 37329 CG31522 3 Viable 
ELO 30179 CG6921 2 Viable 
ELO 43091 CG5278 2 Viable 
ELO 48138 CG2781 3 Viable 
BALS 47520 CG3971 3 Lethal 
Table 3: RNAi responder lines 
 
3.2 Preliminary Crosses with all RNAi lines 
 The RNAi lines, as mentioned before, were crossed to a variety of GAL4 drivers to 
assess the effects of gene specific knockdown for the selected elongases. The results from those 
crosses are presented in Table 4.  
 
 CG 31522 CG 31523 CG 6921 CG 2781 CG 5278 CG 3971 
Cy2GAL4 
(follicle cells) 
Low 
viability 
Low 
fertility 
Collapsed 
eggs 
WT WT WT WT 
ActGAL4/CyO 
Ubiquitous 
Lethality  Lethality  Lethality  Lethality  Lethality  Lethality  
TubGAL4/TM3Serr 
(ActGFP) 
Ubiquitous 
Lethality  Lethality  Low 
viability 
Lethality  Lethality  Viable  
  20 
C155GAL4 
Neuronal 
Abnormal 
behavior 
(sit still 
phenotype) 
WT WT WT WT WT 
A9GAL4 
Wings 
Viable  Viable  Viable Viable Viable Viable 
EnGAL4 
Wings  
Viable Lethal  Viable  Viable Viable Viable 
GMRGAL4 
Eyes  
Rough 
eyes 
Rough 
eyes 
Rough 
eyes 
Rough 
eyes 
Rough 
eyes 
WT 
MS1096 
Wings  
Viable, 
inward curl 
Pharate 
lethality, 
extreme 
wing 
damage in 
escapers 
Viable, 
little 
inward 
curl 
Viable, 
little 
inward 
curl 
Viable, 
slight curl 
Viable, 
WT 
040//CyOGAL4 
Eyes  
Rough 
eyes 
Rough 
eyes 
Rough 
eyes 
Rough 
eyes 
Rough 
eyes 
WT 
P{GawB}OK376 
Oenocytes  
sit still 
phenotype 
Viable, 
WT 
Viable, 
WT 
Larval 
lethality 
Viable, 
WT 
Viable, 
WT 
P{GawB}T80 
3rd instar imaginal 
discs 
Lethal  Lethal  Low 
viability 
Larval 
lethal 
Viable, 
WT 
Viable, 
WT 
P{GawB} C179 
Embryonic 
mesoderm, larval 
muscles and wing 
imaginal discs 
WT WT Pharate 
lethality 
Larval 
lethal 
Lethal WT 
Table 4: Preliminary Data from RNAi crosses with GAL4 drivers 
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3.3 Crossing CG31522 to neuronal, glial and muscle drivers 
 Knockdown of CG31522 was found produce interesting behavioral phenotypes with two 
drivers (C155 and OK376).  In both cases adults underwent premature death (~3 days after 
eclosion) and exhibited numerous abnormal behaviors – including remaining still (no flying, 
minimal crawling), twitching, appearing disoriented with little response to external stimuli, and 
lack of feeding. To further address the role of CG31522 knockdown was generated with a 
number of other neuronal, glial and muscle drivers to observe any possible phenotypes. The data 
from those crosses is presented in table 5. 
  22 
 
 
 Tissue expressed in Observed Phenotype 
ActGAL4 Ubiquitous Lethality 
ActGAL4TubGAL80 Ubiquitous Lethality 
C155GAL4 Nervous system “sit still” phenotype 
OK376 Oenocytes “sit still” phenotype 
P{GawB}477, P{UAS-
mcD8::GFP.L} LL5 
Subset of dendritic 
arborization neurons 
WT 
P{GawB}109(2)80, 
P{UAS-mcD8::GFP.L} 
LL5 
Multiple dendritic neurons, 
oenocytes and chordotonal 
organs 
WT 
P{GawB} D42 Motor neurons WT 
P{GAL4-sli.S}3 Embryonic midline glial cells 
and MP1 neurons 
“sit still” phenotype 
P{GAL4}repo Pan-glial cells, except midline 
glia  
WT 
P{GAL4-sim.S} Ventral midline glial cells WT 
P{GawB}4G Neuronal subset, mostly in 
larval ventral ganglion region 
WT 
P{GawB}(3)[31-1] Embryonic peripheral nervous 
system, CNS, neuroblasts 
WT 
P{GawB}how24B Mesoderm, somatic muscles 
in larvae 
WT 
P{GAL4-Mef2.R} Myoblasts, somatic muscles, 
mesoderm 
WT 
P{GAL4-Mhc.W} Larval muscle system WT 
Table 5: Data from crossing CG31522 to neuronal, glial and muscle cell drivers 
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From the data, the behavioral phenotype presents itself only when CG31522 is knocked 
down in specific tissues - namely neural cells. Moreover, when the elongase is knocked down 
ubiquitously, lethality is observed suggesting it is also required for viability.  Based on the 
behavioral phenotype, I have decided to tentatively name this gene sit still (sits). 
 
3.4 Behavioral Assays 
 As mentioned before, the selection of CG31522 for further testing was based upon the 
behavioral phenotype observed upon knockdown with neuronal and midline glial drivers. The 
progeny from these crosses were observed to stay quite still, not flying, grooming in their 
position, occasionally twitching, and dying within a few days of eclosion due to the lack of 
eating or mating. In comparison, wild type flies and control lines (RNAi responder or GAL4 
driver only) flies were very active, flying around and eating/mating normally. A behavioral assay 
was developed to quantify the observed phenotypic effects. Ten flies were put into an empty vial, 
vortexed for 10 seconds and observed for a further 15 seconds. In this way, the number of flies 
that uprighted themselves and climbed up could be quantified (Figure 5). 
 
Figure 5: Behavioral effects of CG31522 knockdown (n=50) 
 From Figure 5, it can be seen that neural specific knockdown of CG31522 results in a 
dramatic effect of adult activity.  
 
3.5 Time Shift Assays 
 Flies with the genotype CG31522/C155GAL4 were made to undergo the time shift assay 
as aforementioned (see Materials and Methods for details). Once flies that had undergone distinct 
temperature shifts eclosed, the behavioral assay was performed to quantify the percentage of flies 
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that were able to climb up the sides of the vial after the vortex experiment. The results are 
presented in Figure 6, a graph of an upshift from 20°C to 25°C, and a downshift of 25°C to 20°C, 
at every stage of development in the Drosophila. From this it was determined that CG31522 
activity in neural cells at the pupal stage is essential for wild type adult activity.  
 
 
 
Figure 6: Developmental characteristics of CG31522 activity though temperature shifts analysis 
 
 
3.6 Loss of Function crosses 
Given the phenotype observed for RNAi mediated knockdown of CG31522, I sought to 
identify mutations in this elongase.  Two transposon insertions and a large deficiency including 
CG31522 were identified at the Bloomington Drosophila Stock Center. The location of each 
transposon insertion and the deficiency is shown relative to CG31522 in Figure 7.  Initially the 
viability of each transposon line was determined and then a series of complementation crosses 
was carried out to determine the relative effects of each insertion on CG31522 activity.  The data 
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from these crosses is presented in Table 6.  Of the two insertions, KG01294 is homozygous 
lethal, while DG02703 is homozygous viable and appeared to have no significant behavioral 
effects in adults.  This suggested that KG01294 disrupts the activity of CG31522 and that 
CG31522 activity is essential for viability. Complementation tests between the transposon alleles 
and the deficiency resulted in lethality in both cases, indicating that DG02703 is also an allele of 
CG31522, albeit weaker than KG01294.  It remains to be determined if the phenotype of the two 
alleles in combination is lethality or if this genotype would survive to adulthood and display a 
behavioral phenotype similar to that observed in the knockdown. 
 
Figure 7: Genomic Region for CG31522 
 
 P{SUPor-P} 
CG31522KG01294/ 
TM3Sb 
P{wHy}DG02703 w1118; Df(3R)ED5071, 
P{3'.RS5+3.3'}ED5071/TM6C, 
cu1 Sb1 
P{SUPor-P} 
CG31522KG01294/ 
TM3Sb 
Homozygous 
lethal 
Not done Lethal  
P{wHy}DG02703 Not done Viable Lethal  
Table 6: Complementation crosses for CG31522 
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3.6 Gain of Function Experiments 
 To complement the loss of function analyses presented above transgenic responder lines 
for gain of function studies with CG31522 were generated. From a CG31522 cDNA, a UAS-
CG31522 construct was generated (Figure 8) and a total of eleven transgenic lines were made 
and are currently undergoing mapping and stock construction. Preliminary results with 
unmapped UAS-CG31522 responder lines and neural drivers that would misexpress the gene in 
nerves and glial cells resulted in larval lethality.  
 
Figure 8: UAS-CG31522 
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DISCUSSION 
4.1 Lipid-Related Disorders 
Lipids have been known to be important biologically for construction of cellular 
membranes, intracellular trafficking, cell signaling and hormone production. However, recent 
studies have found links between lipids and neurodegenerative disorders such as Tay-Sachs, 
Niemann-Pick and adrenoleukodystrophy. In such cases, the accumulation of certain lipids in the 
body has been related to these diseases. On a similar note, defects in the lipid biosynthetic 
machinery have been linked to diseases as well, including Stargadt-like macular degeneration. 
Thus, the study of lipids and the biosynthetic enzymes that produce them is crucial to develop 
treatments or cures for such disorders.  
 
4.2 Lipid Elongases and Development 
Elongases, known to be enzymes that make fatty acid chains longer, are specific in their 
functions with respect to the fatty acids they produce. In relation to lipid biosynthesis, not much 
is known about these enzymes, apart from the fact that C16 fatty acid chains are made in the 
cytoplasm and serve as the precursor for other longer fatty acids. Elongases themselves act in the 
endoplasmic reticulum of cells, and are thought to play a role in the condensation step of fatty 
acid elongation (Jakobsson A et al., 2006). Although we have gained recent insight into the 
mechanism of fatty acid elongation by elongases, their roles in development still remain poorly 
understood. Only three of the known 7 human elongases are known to have specific functions. 
ELOVL3 is known to be vital for hair and skin development, with deletion of the gene resulting 
in hair and skin permeability defects (Westerberg R et al., 2004). ELOVL4 has been linked to 
both skin permeability barrier function - null mutations result in neonatal lethality and Stargadt-
like macular dystrophy linked to a dominant ELOVL4 mutation (Li W et al., 2007). Finally, 
ELOVL6 has been related to insulin resistance in obesity-induced diabetes (Matsuzaka T et al., 
2007).  Thus for the elongases that have been investigated, important developmental and 
physiological roles have been ascribed to them.  It is clear that these enzymes have specific 
functions, but how and why this specificity exists remains to be determined. 
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4.3 Sit Still- fatty acids, neural development and behavior 
Through my work on sits, it is clear that the gene is required for proper neural 
development. Specifically, the temperature shifts and knockdown with sliGAL4 support the 
notion that sits is required during pupal development and in midline glial cells. This is consistent 
with studies that show extensive glial re-wiring takes place during metamorphosis, i.e. pupal 
stages.  
The current phenotype of sits knockdown may present a working model for multiple 
sclerosis (MS). In MS, the damage occurs in the fatty myelin layer (produced by Schwann cells, 
a type of glial cell) ensheathing the axons, which may result in failure of signal propagation. 
Several of the symptoms are similar between MS and the sits phenotype - such as twitching, 
severe inactivity, paralysis, disorientation and premature death. Moreover, it appears that this is a 
developmental defect, since knockdown of sits in adults has no effect on behavior, whereas 
knockdown during development results in the classic sits behavioral phenotype. Since 
knockdown during re-wiring of the nervous system, especially that of glial cells, is crucial to 
produce the phenotype; one simple hypothesis is that glial cell function is compromised leading 
to neuronal degeneration and therefore this may be an excellent in vivo model for MS. At the 
moment, not enough evidence about the disease itself or the cellular basis for the sits phenotype 
exists to argue this conclusively. There are current studies relating MS to viral infections, 
inflammatory lesions and axonal loss. Arguments exist that claim both environmental and 
genetic factors may be responsible for the disease. However, much still remains to be uncovered 
(Kalman B & Lublin FD, 1999). Thus, the next function becomes to test whether the sits 
phenotype is, in fact, a good model for multiple sclerosis. Important tools to do so would be 
identifying loss-of-function mutations in sits that phenocopy the RNAi effects and gain-of-
function tools for sits as well.  I have recently achieved both of these aims and thus the lab is 
well positioned to test the relevance of sits to MS in the near future.   
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APPENDIX 
CG6921 
RNAi trigger 
CAGTTCGTCCTCATCCTGGGCTACATGCTGACCGTGGGCGCCAAGGGCTGCAACATG
CCCAAGACACTGACCTTCTTCTTCGTGGGCAACACGGTCATCTTCCTTTACCTGTTCG
GCAATTTCTATCGCAAGACCTACAAGAAGGCCAAGTCCGTGGATGGAGGCAGTCGC
ACCACCGGCAGTAGTTTGGCTCAATCCGCTCTGCGTGCCGCCGGCGGTATGGGTTGC
ATGCCGCAGACCATGAACGCCGGTAAGCATCTGCTCCAGAATGGCCAGGTCGGAAA
GGCGTACATCGATCTGAACAACAACAGCGTGAAGCCCATGAAGCTGGAATGA 
Coding sequence: 
ATGACGAACTACATAAAGATTGTCGAGGAGCGAATCTCCGGCCTCTCAAAAGGAGT
GGATGAGACGGTGGACAGCTGGTTCCTAATGAGCTCACCTATGCCCGTGGTGGCCGT
GGTTCTCGTCTATCTGGCGTTTGTTCTGAAAATCGGACCCGAGTACATGAAGAATCG
CAAGCCCATGGACCTCAAGCGCATCATGGTGTTCTATAATGCCTTTCAGGTCTTGTA
CTCCATTTGGATGTGCCGCACGTCCATCCAAGAGAGCAATGTGATGGCGTCGATCTT
CTCGAAGAAGTGCGAGATTAACCGCACCAGGGAGCAGAATCTGACCCTCTATTCCG
GTGCCTGGTTCTACTTTTTCTCGAAGATCATCGATCTGCTGGACACGACGTTCTTTGT
GCTGCGCAAGAAGGACAACCAGGTGTCCTTCCTACACGTGTACCATCACACCATCAC
GGTGCTCTTCTCCTGGGGCTACCTGAAGTACGCTCCCGGCGAGCAGGGCGTGATCAT
TGGCATTCTCAACTCGGGCGTGCACATTATCATGTACTTCTACTACATGGTGGCCGC
AATGGGACCCCAGTACCAGAAGTACCTGTGGTGGAAGAAGTACATGACCAGCATCC
AGCTGATCCAGTTCGTCCTCATCCTGGGCTACATGCTGACCGTGGGCGCCAAGGGCT
GCAACATGCCCAAGACACTGACCTTCTTCTTCGTGGGCAACACGGTCATCTTCCTTT
ACCTGTTCGGCAATTTCTATCGCAAGACCTACAAGAAGGCCAAGTCCGTGGATGGA
GGCAGTCGCACCACCGGCAGTAGTTTGGCTCAATCCGCTCTGCGTGCCGCCGGCGGT
ATGGGTTGCATGCCGCAGACCATGAACGCCGGTAAGCATCTGCTCCAGAATGGCCA
GGTCGGAAAGGCGTACATCGATCTGAACAACAACAGCGTGAAGCCCATGAAGCTGG
AATGA 
Protein sequence: 
M  T  N  Y  I  K  I  V  E  E  R  I  S  G  L  S  K  G  V  D  E  T  V  D  S  W  F  L  M  S  S  P  M  P  
V  V  A  V  V  L  V  Y  L  A  F  V  L  K  I  G  P  E  Y  M  K  N  R  K  P  M  D  L  K  R  I  M  V  
F  Y  N  A  F  Q  V  L  Y  S  I  W  M  C  R  T  S  I  Q  E  S  N  V  M  A  S  I  F  S  K  K  C  E  I  
N  R  T  R  E  Q  N  L  T  L  Y  S  G  A  W  F  Y  F  F  S  K  I  I  D  L  L  D  T  T  F  F  V  L  R  
K  K  D  N  Q  V  S  F  L  H  V  Y  H  H  T  I  T  V  L  F  S  W  G  Y  L  K  Y  A  P  G  E  Q  G  
V  I  I  G  I  L  N  S  G  V  H  I  I  M  Y  F  Y  Y  M  V  A  A  M  G  P  Q  Y  Q  K  Y  L  W  W  
K  K  Y  M  T  S  I  Q  L  I  Q  F  V  L  I  L  G  Y  M  L  T  V  G  A  K  G  C  N  M  P  K  T  L  T  
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F  F  F  V  G  N  T  V  I  F  L  Y  L  F  G  N  F  Y  R  K  T  Y  K  K  A  K  S  V  D  G  G  S  R  T  
T  G  S  S  L  A  Q  S  A  L  R  A  A  G  G  M  G  C  M  P  Q  T  M  N  A  G  K  H  L  L  Q  N  G  
Q  V  G  K  A  Y  I  D  L  N  N  N  S  V  K  P  M  K  L  E  
 
 
CG31522 
RNAi trigger 
AGAACGGAGCCCTGGCCAACGGACACGCCAAGCCCAATGGCTACTGCAAGAGCATC
AACGCCCATGACGATCTGGCCATGCCACAGACCACGGAGGCGACAGCGACAGCGAC
GCCCGCATCCAAGGCCAACGGGAGCAGCACCCCGCCGAGCAATGGACATGCCAATG
GGGTGGAGAACGTCTACAAGCAGGTGGCCAACGGCAGCGCGCACAAGGGGTCCAA
CGGAGGACTGAGCAACGGGTATGCCACCAAGCTGCTGGACGACGCCTCCCAGGAGC
TGAAACAGCGGAAGACGCCGA 
Coding sequence: 
ATGGCCTTAATTATGAAATACATCGACAGCATAAGCAGATACATGGACTCACATAGT
GACTCGAGGACAAAGGGCTGGCCCATGATGTCGTCCCCATTCCCCACACTGGCCGTT
TGCCTCACATATGTCTATCTGGTCAAGGTGCTGGGACCCCGATTAATGGAGAACCGA
AAGCCTCTGAATCTGCAAAACACTCTAGTCATGTACAATGCCATACAGGTTGTATTT
AGCGCATGGCTGTTTTATGAGTGCTTGATGGGCGGCTGGTGGGGCTCGTACAGCTTC
CGGTGCCAGCCGGTGGACTACACAGATAGTCCCACATCCCGGAGAATGGTTCATGC
CTGCTGGTGGTACTACTTCTCGAAGTTTACAGAATTCATGGATACGATTTTCTTCGTG
TTGCGCAAGAAGTCGAGCCAAGTTACCACACTGCACGTCATCCATCACGGCTGCATG
CCCATGTCGGTCTGGTTCGGCGTCAAGTTCACACCGGGTGGTCACAGCACCTTCTTC
GGCCTGCTCAACACCTTCGTCCACATCGTGATGTACACCTACTACATGTTCTCCGCC
ATGGGTCCGCAGTACCAGAAATACCTCTGGTGGAAGAAGTACCTGACCACTCTGCA
GATGGTCCAGTTCATCTTGATCATGGTGCACGCCTTCCAGCTGCTCTTCATCGATTGC
AACTACCCGAAGGCGTTCGTCTGGTGGATTGGCATGCATGCCGTCATGTTCTTCTTCC
TGTTCAACGAGTTCTACAAGGCAGCCTACAGGAGCCGCATGATGAAAAAGAACGGA
GCCCTGGCCAACGGACACGCCAAGCCCAATGGCTACTGCAAGAGCATCAACGCCCA
TGACGATCTGGCCATGCCACAGACCACGGAGGCGACAGCGACAGCGACGCCCGCAT
CCAAGGCCAACGGGAGCAGCACCCCGCCGAGCAATGGACATGCCAATGGGGTGGA
GAACGTCTACAAGCAGGTGGCCAACGGCAGCGCGCACAAGGGGTCCAACGGAGGA
CTGAGCAACGGGTATGCCACCAAGCTGCTGGACGACGCCTCCCAGGAGCTGAAACA
GCGGAAGACGCCGAAATAA 
Protein Sequence: 
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M  A  L  I  M  K  Y  I  D  S  I  S  R  Y  M  D  S  H  S  D  S  R  T  K  G  W  P  M  M  S  S  P  F  P  
T  L  A  V  C  L  T  Y  V  Y  L  V  K  V  L  G  P  R  L  M  E  N  R  K  P  L  N  L  Q  N  T  L  V  
M  Y  N  A  I  Q  V  V  F  S  A  W  L  F  Y  E  C  L  M  G  G  W  W  G  S  Y  S  F  R  C  Q  P  V  
D  Y  T  D  S  P  T  S  R  R  M  V  H  A  C  W  W  Y  Y  F  S  K  F  T  E  F  M  D  T  I  F  F  V  
L  R  K  K  S  S  Q  V  T  T  L  H  V  I  H  H  G  C  M  P  M  S  V  W  F  G  V  K  F  T  P  G  G  
H  S  T  F  F  G  L  L  N  T  F  V  H  I  V  M  Y  T  Y  Y  M  F  S  A  M  G  P  Q  Y  Q  K  Y  L  
W  W  K  K  Y  L  T  T  L  Q  M  V  Q  F  I  L  I  M  V  H  A  F  Q  L  L  F  I  D  C  N  Y  P  K  
A  F  V  W  W  I  G  M  H  A  V  M  F  F  F  L  F  N  E  F  Y  K  A  A  Y  R  S  R  M  M  K  K  
N  G  A  L  A  N  G  H  A  K  P  N  G  Y  C  K  S  I  N  A  H  D  D  L  A  M  P  Q  T  T  E  A  T  
A  T  A  T  P  A  S  K  A  N  G  S  S  T  P  P  S  N  G  H  A  N  G  V  E  N  V  Y  K  Q  V  A  N  
G  S  A  H  K  G  S  N  G  G  L  S  N  G  Y  A  T  K  L  L  D  D  A  S  Q  E  L  K  Q  R  K  T  P  
K  
 
 
CG31523 
RNAi trigger 
GCCATTTTCACCCACCAGTTCCAGCTTTTGTTCCGCGAATGTGATTACCCCAAGGGCT
TCATGGTCTGGATCGGATTGCACGGCGTTATGTTCCTGTTCCTGTTCTCCGACTTTTA
CAAAGCGAAATATCTCAACGCAGCTCGACGTCGCCGGCAGGCGGTCAAGGCCAATG
GCTATGCCAACGGCTCGGCTTCGAATGGGCACAGCAAGCATCTTGGAGAGGGTGAC
GCCCTGATTGCAAACGGTTGCAATACTGGGGCTTGCATGCCGGTGATGGAGGACGA
GTACGTCAAAAGCAAGGGGCAATCG 
Coding Sequence: 
ATGGCAATCATACTGCAAGAAGCCCAGAAGTGGTATCGGGACCTAATGGACAATAA
AAGCGATCCTCGCGTTAACGACTTCTTTCTGCTATCCTCGCCACTGCCCACACTTTGT
ATGTGCATATTCTATGCCTACTTCAGCAAATCCCTGGGGCCCAGGCTGATGGCCAAA
CGGAAACCGATGGAGTTGCGATCTGTTTTAGTTGTATACAACGCGATACAAACAATA
TTTAGCGCGTGGATCTTTTATGAGTACTTAATGAGCGGATGGTGGGGCCACTACAGC
TTAAAGTGTCAGCCCGTTGACTATAGCACCACTGGCTTGGCCATGCGGATGGTCAAC
ATTTGCTGGTGGTACTACATATCTAAGTTCACCGAGTTCTTCGACACACTCTTCTTCA
TTCTGCGAAAAAAGAACGAGCACGTCTCCACACTACACGTCATCCATCACGGCTGC
ATGCCGTTCTCCGTCTGGATGGGTCTGAAGTTTGCGCCAGGCGGTCATAGCACTTTC
TTTGCCCTTCTCAACTCGTTTGTGCACATTGTAATGTATTTCTACTACATGATCGCCG
CCATGGGTCCAAAGTACCAGAAGTACATCTGGTGGAAGAAGTACCTGACCACCTTC
CAAATGGTTCAATTCGTGGCCATTTTCACCCACCAGTTCCAGCTTTTGTTCCGCGAAT
GTGATTACCCCAAGGGCTTCATGGTCTGGATCGGATTGCACGGCGTTATGTTCCTGT
  34 
TCCTGTTCTCCGACTTTTACAAAGCGAAATATCTCAACGCAGCTCGACGTCGCCGGC
AGGCGGTCAAGGCCAATGGCTATGCCAACGGCTCGGCTTCGAATGGGCACAGCAAG
CATCTTGGAGAGGGTGACGCCCTGATTGCAAACGGTTGCAATACTGGGGCTTGCATG
CCGGTGATGGAGGACGAGTACGTCAAAAGCAAGGGGCAATCGAATGGTGCCTACAA
GGAGGGCTTCTTCAAGGAGGGCGTGTTATCCAACAACGATGCCATCTTCAACCCGGA
CAGCAGTAGTTCTAGTCTGCACCAGCGCAAAGTCAAATAA 
Protein Sequence: 
M  A  I  I  L  Q  E  A  Q  K  W  Y  R  D  L  M  D  N  K  S  D  P  R  V  N  D  F  F  L  L  S  S  P  L  
P  T  L  C  M  C  I  F  Y  A  Y  F  S  K  S  L  G  P  R  L  M  A  K  R  K  P  M  E  L  R  S  V  L  V  
V  Y  N  A  I  Q  T  I  F  S  A  W  I  F  Y  E  Y  L  M  S  G  W  W  G  H  Y  S  L  K  C  Q  P  V  
D  Y  S  T  T  G  L  A  M  R  M  V  N  I  C  W  W  Y  Y  I  S  K  F  T  E  F  F  D  T  L  F  F  I  L  
R  K  K  N  E  H  V  S  T  L  H  V  I  H  H  G  C  M  P  F  S  V  W  M  G  L  K  F  A  P  G  G  H  
S  T  F  F  A  L  L  N  S  F  V  H  I  V  M  Y  F  Y  Y  M  I  A  A  M  G  P  K  Y  Q  K  Y  I  W  
W  K  K  Y  L  T  T  F  Q  M  V  Q  F  V  A  I  F  T  H  Q  F  Q  L  L  F  R  E  C  D  Y  P  K  G  
F  M  V  W  I  G  L  H  G  V  M  F  L  F  L  F  S  D  F  Y  K  A  K  Y  L  N  A  A  R  R  R  R  Q  
A  V  K  A  N  G  Y  A  N  G  S  A  S  N  G  H  S  K  H  L  G  E  G  D  A  L  I  A  N  G  C  N  T  
G  A  C  M  P  V  M  E  D  E  Y  V  K  S  K  G  Q  S  N  G  A  Y  K  E  G  F  F  K  E  G  V  L  S  
N  N  D  A  I  F  N  P  D  S  S  S  S  S  L  H  Q  R  K  V  K  •  
 
 
CG2781 
RNAi trigger 
CTCGCCGTTCCCCACGATAGCTATCAGTCTGACATACGCGTACATCGTAAAGGTACT
CGGACCCAAGCTCATGGAAAACAGAAAGCCTTTCGAGCTCCGCAAAGTCTTGATCG
TCTACAATGCAGCGCAGGTTATCTTCAGTGCCTGGCTTTTTTACGAGTCCTGCATAGG
TGGATGGCTCAACGGCTATAACTTGCGATGCGAGCCCGTTAATTATTCCTACTCGCC
CAAAGCTATTCGTACCGCTGAGGGCTGCTGGTGGTACTACTTCTCAAAGTTCACCGA
GTTCTTCGACACCTTCTTCTTTGTGATGCGTAAGCGGTACGATCAAGTGTCCACGTTG
CACGTGATCCACCACGGCATCATGCCCGTCTCCGTCTGGTGGGGCGTCAAGT 
Coding sequence: 
ATGGATTACCTCACAATGTTCTACGACGGCTGGCGGGATCTGATGGACAACAAATCG
GATCCGCGAACACGAGACTACCCGCTCATGAGCTCGCCGTTCCCCACGATAGCTATC
AGTCTGACATACGCGTACATCGTAAAGGTACTCGGACCCAAGCTCATGGAAAACAG
AAAGCCTTTCGAGCTCCGCAAAGTCTTGATCGTCTACAATGCAGCGCAGGTTATCTT
CAGTGCCTGGCTTTTTTACGAGTCCTGCATAGGTGGATGGCTCAACGGCTATAACTT
  35 
GCGATGCGAGCCCGTTAATTATTCCTACTCGCCCAAAGCTATTCGTACCGCTGAGGG
CTGCTGGTGGTACTACTTCTCAAAGTTCACCGAGTTCTTCGACACCTTCTTCTTTGTG
ATGCGTAAGCGGTACGATCAAGTGTCCACGTTGCACGTGATCCACCACGGCATCATG
CCCGTCTCCGTCTGGTGGGGCGTCAAGTTCACCCCCGGTGGCCACTCGACCTTCTTT
GGCTTCCTGAACACCTTCGTGCACATCTTCATGTACGCCTACTACATGCTGGCCGCC
ATGGGACCCAAGGTGCAGAAGTACCTGTGGTGGAAGAAGTACCTGACAGTGATGCA
GATGATCCAGTTCGTCCTGGTTATGGTGCACTCCTTCCAGCTGTTCTTCAAGAACGAC
TGCAACTACCCAATTGGCTTCGCCTACTTCATCGGAGCCCATGCGGTTATGTTCTACT
TCCTGTTCTCAAACTTCTACAAGCGTGCCTATGTGAAACGCGATGGCAAGGACAAAG
CGTCGGTGAAGGCAAACGGACATGCCAACGGACACGTGAAGGCGCTCAAGGACGG
CGATGTGGCGCCAACCAGCAACGGCCAGGCCAACGGCTTCCACAACACCTTCTCCA
AGTTCACCACGGATATGTGCAATCCGGCCCTGAACTCCTCGACGAGACAGCGTGTGC
TCGTGAACGCCGGCAACAAGTGA 
Protein Sequence: 
M  D  Y  L  T  M  F  Y  D  G  W  R  D  L  M  D  N  K  S  D  P  R  T  R  D  Y  P  L  M  S  S  P  F  
P  T  I  A  I  S  L  T  Y  A  Y  I  V  K  V  L  G  P  K  L  M  E  N  R  K  P  F  E  L  R  K  V  L  I  V  
Y  N  A  A  Q  V  I  F  S  A  W  L  F  Y  E  S  C  I  G  G  W  L  N  G  Y  N  L  R  C  E  P  V  N  
Y  S  Y  S  P  K  A  I  R  T  A  E  G  C  W  W  Y  Y  F  S  K  F  T  E  F  F  D  T  F  F  F  V  M  R  
K  R  Y  D  Q  V  S  T  L  H  V  I  H  H  G  I  M  P  V  S  V  W  W  G  V  K  F  T  P  G  G  H  S  
T  F  F  G  F  L  N  T  F  V  H  I  F  M  Y  A  Y  Y  M  L  A  A  M  G  P  K  V  Q  K  Y  L  W  W  
K  K  Y  L  T  V  M  Q  M  I  Q  F  V  L  V  M  V  H  S  F  Q  L  F  F  K  N  D  C  N  Y  P  I  G  
F  A  Y  F  I  G  A  H  A  V  M  F  Y  F  L  F  S  N  F  Y  K  R  A  Y  V  K  R  D  G  K  D  K  A  
S  V  K  A  N  G  H  A  N  G  H  V  K  A  L  K  D  G  D  V  A  P  T  S  N  G  Q  A  N  G  F  H  N  
T  F  S  K  F  T  T  D  M  C  N  P  A  L  N  S  S  T  R  Q  R  V  L  V  N  A  G  N  K  
 
CG3971 
RNAi trigger 
AATCCGCCCAGGTTCATCTCGATGATCATCACGTCGCTGCAGCTGGCTCAGATGATC
ATCGGATGTGCGATCAACGTGTGGGCCAATGGCTTCCTGAAGACGCACGGCACCTC
CTCCTGTCACATCTCGCAGCGCAACATCAATCTGTCGATCGCCATGTACTCCAGCTA
CTTTGTCCTGTTCGCGCGCTTCTTCTACAAGGCGTACCTGGCGCCCGGTGGTCACAA
GAGCCGGCGCATGGCCGCCTCCCTGGCAGCCCAGAATGTGGTCAAGCAGTCGAGCA 
Coding sequence: 
ATGATCAACATGGACATTAGCGTTACGCCCAATTACTCGTACATCTTCGACTTCGAG
AACGATTTCATACACCAGCGGACGCGCAAATGGATGCTAGAGAACTGGACATGGGT
  36 
GTTCTACTACTGCGGCATCTACATGCTGGTCATCTTCGGTGGTCAGCACTTTATGCAA
AATCGGCCTAGATTCCAATTGCGCGGCCCGCTGATCATATGGAACACCTTGCTGGCC
ATGTTCAGCATCATGGGTGCTGCCCGAACGGCGCCGGAGCTGATTCACGTGCTGCGT
CACTACGGACTCTTCCACTCCGTCTGCGTGCCCAGCTACATCGAGCAAGATCGCGTG
TGCGGCTTCTGGACCTGGCTCTTCGTGCTCAGCAAACTGCCGGAGCTGGGCGACACG
ATATTCATTGTGCTCCGCAAGCAGCCACTCATCTTTTTGCACTGGTATCACCACATCA
CCGTGCTGATCTACTCGTGGTTCAGCTATACGGAATATACCAGCTCTGCCCGCTGGT
TCATCGTGATGAACTACTGCGTGCACTCGGTGATGTACAGCTACTATGCTCTGAAGG
CGGCCCGCTTCAATCCGCCCAGGTTCATCTCGATGATCATCACGTCGCTGCAGCTGG
CTCAGATGATCATCGGATGTGCGATCAACGTGTGGGCCAATGGCTTCCTGAAGACGC
ACGGCACCTCCTCCTGTCACATCTCGCAGCGCAACATCAATCTGTCGATCGCCATGT
ACTCCAGCTACTTTGTCCTGTTCGCGCGCTTCTTCTACAAGGCGTACCTGGCGCCCGG
TGGTCACAAGAGCCGGCGCATGGCCGCCTCCCTGGCAGCCCAGAATGTGGTCAAGC
AGTCGAGCAGCCCCCAGCAGGCCAGCGAGAGCTCCAAGTTCATCGGCGCTGGCGAG
GATCAGGCAGCCTATCTGCGCAAGGCCAAGGCGCAGTAA 
Protein Sequence: 
M  I  N  M  D  I  S  V  T  P  N  Y  S  Y  I  F  D  F  E  N  D  F  I  H  Q  R  T  R  K  W  M  L  E  N  
W  T  W  V  F  Y  Y  C  G  I  Y  M  L  V  I  F  G  G  Q  H  F  M  Q  N  R  P  R  F  Q  L  R  G  P  
L  I  I  W  N  T  L  L  A  M  F  S  I  M  G  A  A  R  T  A  P  E  L  I  H  V  L  R  H  Y  G  L  F  H  
S  V  C  V  P  S  Y  I  E  Q  D  R  V  C  G  F  W  T  W  L  F  V  L  S  K  L  P  E  L  G  D  T  I  F  
I  V  L  R  K  Q  P  L  I  F  L  H  W  Y  H  H  I  T  V  L  I  Y  S  W  F  S  Y  T  E  Y  T  S  S  A  R  
W  F  I  V  M  N  Y  C  V  H  S  V  M  Y  S  Y  Y  A  L  K  A  A  R  F  N  P  P  R  F  I  S  M  I  I  
T  S  L  Q  L  A  Q  M  I  I  G  C  A  I  N  V  W  A  N  G  F  L  K  T  H  G  T  S  S  C  H  I  S  Q  
R  N  I  N  L  S  I  A  M  Y  S  S  Y  F  V  L  F  A  R  F  F  Y  K  A  Y  L  A  P  G  G  H  K  S  R  
R  M  A  A  S  L  A  A  Q  N  V  V  K  Q  S  S  S  P  Q  Q  A  S  E  S  S  K  F  I  G  A  G  E  D  Q  
A  A  Y  L  R  K  A  K  A  Q  
 
CG5278 
RNAi trigger 
ACGAGGGCGTGGTCATCTGGCAGTACTACAGCTGGCGGTGCCAGCCGGTTGATTGGT
CCCGCACACCCAAGGCGTATCGTGAGGCGCGCGTCGTCTATGTCTACTATCTGGCCA
AGATTACCGAGCTGCTGGACACCATTTTCTTTGTGCTGCGCAAGAATGACCGACAGG
TGACCTTCCTGCATGTCTACCATCACACGGTGATGCCCATGATCAGCTGGGGCACCA
GCAAGTACTATCCCGGCGGACATGGCACCTTCATTGGCTGGATCAACTCCTTCGTGC
ACATTATCATGTACTCCTACTACTTCCTCTCCGCCTTCGG 
 
  37 
Coding Sequence: 
ATGGCAGCCGTCAACGCAACACAGGTGGACTATTGGAATTTTCTGTTCACCGATCTG
GCAGATCCCCGCACCAATGACTGGTTCCTGATCAAGTCGCCACTGCCCCTGCTGGGC
ATCCTGGCCTTCTATCTCTTCTTCGTGCTGTCCTGGGGACCCAAGTTCATGAAGGATC
GCAAACCCTTCAAGCTGGAACGCACCCTGCTCGTCTACAATTTCTTCCAGGTAGCCC
TCAGTGTTTGGATGGTCTACGAGGGCGTGGTCATCTGGCAGTACTACAGCTGGCGGT
GCCAGCCGGTTGATTGGTCCCGCACACCCAAGGCGTATCGTGAGGCGCGCGTCGTCT
ATGTCTACTATCTGGCCAAGATTACCGAGCTGCTGGACACCATTTTCTTTGTGCTGCG
CAAGAATGACCGACAGGTGACCTTCCTGCATGTCTACCATCACACGGTGATGCCCAT
GATCAGCTGGGGCACCAGCAAGTACTATCCCGGCGGACATGGCACCTTCATTGGCT
GGATCAACTCCTTCGTGCACATTATCATGTACTCCTACTACTTCCTCTCCGCCTTCGG
ACCCCAGATGCAGAAGTATCTGTGGTGGAAGAAGTACATCACCAACCTGCAGATGA
TCCAGTTCTGCTGCGCCTTCATCCACCAGACGCAGCTGTTGTACACGGATTGTGGGT
ATCCCAGGTGGTCGGTGTGCTTTACCCTGCCCAACGCGGTGTTCTTCTACTTCCTGTT
CAACGACTTCTACCAGAAGTCCTACAAGAAGAAGCAGGCTGCTGCCAAGGAGAAGG
CTCTGTCGGCGGATAACAATAATGATGGATGTGCCAAGGACCTCAACAAGGCAATT
CAGCTGCAGCAGGAGAAGCAGAAGGCCTTGTAA 
Protein Sequence: 
M  A  A  V  N  A  T  Q  V  D  Y  W  N  F  L  F  T  D  L  A  D  P  R  T  N  D  W  F  L  I  K  S  P  
L  P  L  L  G  I  L  A  F  Y  L  F  F  V  L  S  W  G  P  K  F  M  K  D  R  K  P  F  K  L  E  R  T  L  
L  V  Y  N  F  F  Q  V  A  L  S  V  W  M  V  Y  E  G  V  V  I  W  Q  Y  Y  S  W  R  C  Q  P  V  D  
W  S  R  T  P  K  A  Y  R  E  A  R  V  V  Y  V  Y  Y  L  A  K  I  T  E  L  L  D  T  I  F  F  V  L  R  
K  N  D  R  Q  V  T  F  L  H  V  Y  H  H  T  V  M  P  M  I  S  W  G  T  S  K  Y  Y  P  G  G  H  G  
T  F  I  G  W  I  N  S  F  V  H  I  I  M  Y  S  Y  Y  F  L  S  A  F  G  P  Q  M  Q  K  Y  L  W  W  K  
K  Y  I  T  N  L  Q  M  I  Q  F  C  C  A  F  I  H  Q  T  Q  L  L  Y  T  D  C  G  Y  P  R  W  S  V  C  
F  T  L  P  N  A  V  F  F  Y  F  L  F  N  D  F  Y  Q  K  S  Y  K  K  K  Q  A  A  A  K  E  K  A  L  
S  A  D  N  N  N  D  G  C  A  K  D  L  N  K  A  I  Q  L  Q  Q  E  K  Q  K  A  L  
 
 
 
 
 
 
 
  38 
GH22993 (full length sequence) 
CGATTTCCACACAAAATTCCTAGTCTGCTGCCGAGTACTACCACTGCAAAACGAACT
CAAATTCGAAAACCCGCTTGGCACCGCATCAAATGCACTAAGTCCCAAGCACTAAA
ATTATCCAGATCAGAAGCAAAACCAAGACTTTAACCACCAACCAATTGTACAATCA
AAAATCAGCAAGGAACACGAACTACAAACCAAAGGAATAGTAGGACTCCGCAGTC
GGCGACAAACAGTAACCACTACTCAACAACACAATGGCCTTAATTATGAAATACAT
CGACAGCATAAGCAGATACATGGACTCACATAGTGACTCGAGGACAAAGGGCTGGC
CCATGATGTCGTCCCCATTCCCCACACTGGCCGTTTGCCTCACATATGTCTATCTGGT
CAAGGTGCTGGGACCCCGATTAATGGAGAACCGAAAGCCTCTGAATCTGCAAAACA
CTCTAGTCATGTACAATGCCATACAGGTTGTATTTAGCGCATGGCTGTTTTATGAGAT
AGGCATTTCCGGTTGGCTAACTGGACATTATAGCTTCCGATGTCAGCCAGTCGACTA
TAGTAATAATCCTAGAACGTTAAGGATGGTTCATGCCTGCTGGTGGTACTACTTCTC
GAAGTTTACAGAATTCATGGATACGATTTTCTTCGTGTTGCGCAAGAAGTCGAGCCA
AGTTACCACACTGCACGTCATCCATCACGGCTGCATGCCCATGTCGGTCTGGTTCGG
CGTCAAGTTCACACCGGGTGGTCACAGCACCTTCTTCGGCCTGCTCAACACCTTCGT
CCACATCGTGATGTACACCTACTACATGTTCTCCGCCATGGGTCCGCAGTACCAGAA
ATACCTCTGGTGGAAGAAGTACCTGACCACTCTGCAGATGGTCCAGTTCATCTTGAT
CATGGTGCACGCCTTCCAGCTGCTCTTCATCGATTGCAACTACCCGAAGGCGTTCGT
CTGGTGGATTGGCATGCATGCCGTCATGTTCTTCTTCCTGTTCAACGAGTTCTACAAG
GCAGCCTACAGGAGCCGCATGATGAAAAAGAACGGAGCCCTGGCCAACGGACACG
CCAAGCCCAATGGCTACTGCAAGAGCATCAACGCCCATGACGATCTGGCCATGCCA
CAGACCACGGAGGCGACAGCGACAGCGACGCCCGCATCCAAGGCCAACGGGAGCA
GCACCCCGCCGAGCAATGGACATGCCAATGGGGTGGAGAACGTCTACAAGCAGGTG
GCCAACGGCAGCGCGCACAAGGGGTCCAACGGAGGACTGAGCAACGGGTATGCCA
CCAAGCTGCTGGACGACGCCTCCCAGGAGCTGAAACAGCGGAAGACGCCGAAATAA
TATCGGGGCAAGGAGGGGCGGCGCCAGCGCAGAGCTTAGAACACGGCGAGGGCCA
GTAGCGCCAGGAGCTTCCTGAAAAGGAGCGGAGCTCCAAAAGTCATTTCCATAGGC
ACACACAACTTCATTTAACTCACTACTACTACTTCACATCGCAGACCATCCACTTTCG
AAATTCCAAGCCGGGACCGACGTCCATGGGTAGCTGGGGAAATATGCTATGTAAGC
GCGTGAAAACATTGTTAATCCTGACTGCCGAGGGCATTGCGAGGCGGCTTCTCCCAC
AGACCCAAATCCATACACCTGAACATAGAAATATGCGAATGGTCGCTAGCATACCC
AATGGGTGCACCGCACCCATTGAGGCACATGCAAATGTATAGGCATTGCGAATGCA
TATGCACCCATTCTCTAGCCTACTTTTTAAATACGTTTTGTTGCTTCTTTTTCTTTTTT
AGTTGTACAAAGCTTACTTATCATAAGTATCCCAGCGGATTGTATAATACAAGAACA
AATATCGCAAACCAAGATTTTAACTAATCGAAAACGCTAATGGAAGCCCAGCAAAA
TCAATTTAAAAATAAAACTAATGCCAACGCACTTGGATTGTGTGTGAGCAAAGCATT
CAACTATTTAAGCCTAGAATTTAATTTATATGTGTATATTTGCATACATATATTATTG
AAGTAATTGAAAACAGCAGCAGCAGCCTACGGCAAGTTTTGTAAATGTATAGAGCA
AAAACAAGTGTAATTTAAAATTAGACACAATAATTATTAAAAATAAAAGTCATTCA
AAATAAAAAAAAAAAAAAAAAA 
 
 
 
